Call us +91 -7376325889/ 7376335889
Mail
Support
Partners
Careers
Knowledge Center
Downloads
Margin Calculator
Equity
F&O
MF
Online Trading
Open an Account
Back Office
Apply IPO
ABOUT US
SERVICES
MARKETS
Equity
Derivatives
Mutual Fund
IPO
PORTFOLIO
OUR RECOMMENDATIONS
CONTACT US
CALCULATORS
MENU
×
HOME
SERVICES
MARKETS
PORTFOLIO
OUR RECOMMENDATIONS
ABOUT US
SERVICES
CONTACT US
CALCULATORS
Online Trading
Open an Account
Back Office
Apply IPO
Equity Analysis
Company Profile
Price
Volume
Analysis
Company Profile
News Analysis
Corporate Action
Other Markets
Detailed Quotes
Detailed Quotes
Company Snapshot
Company Background
Board of Directors
Profit & Loss
Balance Sheet
Quarterly Results
Key Financial Ratios
Share Holding Pattern
Directors Report
Score Board
MF Holdings
Name Change
Company News
Peer Comparison
Monthly High / Low
Price Chart
Consolidated Quarters
FII Holding
Simple & CAGR Growth
Deliverable Volumes
Company News
Neuland Laboratories Ltd
Industry : Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value(
)
524558
INE794A01010
1081.5200264
NSE Symbol
P/E(TTM)
Mar.Cap(
Cr.)
NEULANDLAB
75.83
19947.21
EPS(TTM)
Face Value(
)
Div & Yield %:
205.02
10
0.09
Back
Ucal Ltd
Greencrest Financial Services standalone net profit declines 69.02% in the September 2024 quarter
Nov 11,2024
Net profit of Greencrest Financial Services declined 69.02% to Rs 1.71 crore in the quarter ended September 2024 as against Rs 5.52 crore during the previous quarter ended September 2023. Sales rose 15.19% to Rs 15.47 crore in the quarter ended September 2024 as against Rs 13.43 crore during the previous quarter ended September 2023.
Particulars
Quarter Ended
Sep. 2024
Sep. 2023
% Var.
Sales
15.47
13.43
15
OPM %
20.43
47.95
-
PBDT
2.38
6.03
-61
PBT
2.38
6.03
-61
NP
1.71
5.52
-69